CAMBRIDGE ANTIBODY TECHNOLOGY TO EXPAND OPERATIONS IN CAMBRIDGE, UK, CREATING OVER 200 NEW JOBS
 

November 7th 2006 Cambridge, UK… Cambridge Antibody Technology (CAT) today announces that it is expanding its operations in Cambridge, UK, by leasing the building currently known as Unit GP15 on Granta Park, the science park near Cambridge, which is already home to two of the company’s facilities.

Unit GP15, which was previously occupied by Millennium Pharmaceuticals who vacated the building in 2003, will provide CAT with an additional 92,000 square feet of state-of-the-art laboratory and associated open-plan office space. The company plans to carry out significant alterations to the internal layout of the building before it moves in, sometime in the next 12 to 15 months.

Hamish Cameron, CAT’s Chief Executive, commented: “This investment in CAT’s future is essential for us to achieve our planned expansion as part of the AstraZeneca group of companies. CAT is on a journey to create an outstanding biopharmaceutical company and is central to AstraZeneca’s plans to establish a major international presence in the research and development of biological therapeutics. Starting next year, CAT will be recruiting a significant number of new staff, across all functions and at all levels, to join our team and this additional space is being prepared to accommodate this growth. Unit GP15 is ideal for us, and when fully occupied will house between 250-300 people. It is a high quality building and, being so close to our existing facilities on Granta Park, it will allow many of our staff to continue to work easily and closely together, an important feature of CAT’s working culture, and one which we will strive to maintain as we grow.”

CAT plans to rename the building before occupying it.

- ENDS-

Notes to Editors:

Cambridge Antibody Technology (CAT):

Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients’ lives.

CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company’s strategy to develop a portfolio of antibody-based drugs.

CAT is part of the AstraZeneca group of companies.

CAT currently employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA.

For more information: www.cambridgeantibody.com

Contacts:

Media relations for Cambridge Antibody Technology Europe:
Sue Charles/Tony Stephenson/Susan Yu
Northbank Communications
t : +44 (0)20 3008 7550
m: +44 (0)7968 726585
e: catpr@northbankcommunications.com 


Media relations for Cambridge Antibody Technology USA:
Brad Miles
BMC Communications (USA)
t : +1 (2)12 477 9007 ext 17

At Cambridge Antibody Technology:
Rowena Gardner, Director of Corporate Communications
t : +44 (0) 1223 471 471
e: rowena.gardner@cambridgeantibody.com